Monitor for the definitive proxy statement (DEF 14A) or subsequent filings for material proposals such as director elections or compensation votes. The board appointment suggests governance focus, but no immediate trading catalyst.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $5.83entry
- T+1 · 7mo ago +3.09%α +1.70% · $6.01
- T+5 · 6mo ago −2.57%α −4.56% · $5.68
- T+20 · 6mo ago −2.40%α −7.36% · $5.69
- T+60 · 4mo ago +10.98%α +8.24% · $6.47
Price Chart
How similar events traded
Executive Summary
Abeona Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) on May 4, 2026, likely supplementing its proxy statement for the upcoming annual meeting. The filing content is predominantly encoded images and cannot be parsed for specific proposals, making the analysis uncertain.
Key Facts
- Form DEFA14A filed on May 4, 2026, as additional definitive proxy soliciting materials.
- Filing content is largely unreadable (encoded graphics), preventing extraction of specific proposals or votes.
- Cross-filing context: an 8-K on April 7, 2026, appointed Keith A. Goldan to the Board and as Audit Committee Chair.
Financial Impact
Not specified
Risk Factors
- Uncertainty due to unreadable filing content
- Potential shareholder proposals or contested matters not visible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001493152-26-021127 |
| Document: 0001493152-26-021127-index-headers.html | 0001493152-26-021127 |
| Document: 0001493152-26-021127-index.html | 0001493152-26-021127 |
| Document: 0001493152-26-021127.txt | 0001493152-26-021127 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers